SIADH
MCID: INP001
MIFTS: 49

Inappropriate Adh Syndrome (SIADH)

Categories: Cancer diseases, Endocrine diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Inappropriate Adh Syndrome

MalaCards integrated aliases for Inappropriate Adh Syndrome:

Name: Inappropriate Adh Syndrome 12 52 15 17 71
Syndrome of Inappropriate Secretion of Antidiuretic Hormone 12 36 32
Syndrome of Inappropriate Antidiuretic Hormone Secretion 12 52
Siadh 52 54
Syndrome of Inappropriate Vasopressin Secretion 12
Syndrome of Inappropriate Antidiuretic Hormone 52
Syndrome of Inappropriate Secretion of Adh 12
Schwartz Bartter Syndrome 52
Dilutional Hyponatremia 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3401
KEGG 36 H01682
NCIt 49 C3988
SNOMED-CT 67 55004003
ICD10 32 E22.2
UMLS 71 C0021141

Summaries for Inappropriate Adh Syndrome

KEGG : 36 The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an endocrine disease, characterized by inappropriately concentrated urine, dilutional hyponatremia, and subsequent manifestations of various central nervous system (CNS) symptoms. Though usually transient, SIADH may be chronic. It is often associated with drug use or a lesion in the central nervous system or lung. SIADH is divided into two categories. One is the ectopic ADH syndrome induced by abnormally secreted arginine vasopressin (ADH/AVP) from cancer cells. Another is the morbidity caused by inappropriately secreted ADH from the pituitary gland. In both situations of SIADH, ADH binds to vasopressin V2 receptors (V2Rs) in renal tubules and thereby increasing water reabsorption. SIADH is difficult to distinguish from cerebral salt wasting syndrome (CSWS), another cause of hyponatremia characterized by renal loss of sodium and decreases in extracellular fluid volume during intracranial disorders. SIADH occurs in the setting of euvolemia, without evidence of renal disease or thyroxine or cortisol deficiency. Treatment options for SIADH include fluid restriction, demeclocycline, urea, frusemide and saline infusion, all of which have their limitations. The introduction of the vasopressin-2 receptor antagonists has allowed clinicians to specifically target the underlying pathophysiology of SIADH.

MalaCards based summary : Inappropriate Adh Syndrome, also known as syndrome of inappropriate secretion of antidiuretic hormone, is related to nephrogenic syndrome of inappropriate antidiuresis and pure autonomic failure, and has symptoms including polyuria An important gene associated with Inappropriate Adh Syndrome is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Vasopressin-regulated water reabsorption. The drugs Tolvaptan and Vasopressins have been mentioned in the context of this disorder. Affiliated tissues include pituitary, lung and kidney, and related phenotypes are behavior/neurological and growth/size/body region

NIH Rare Diseases : 52 Syndrome of inappropriate antidiuretic hormone (SIADH) occurs when an excessive amount of antidiuretic hormone is released resulting in water retention and a low sodium level. It is most common among older people. It has many causes including, but not limited too, pain, stress, exercise, a low blood sugar level, certain disorders of the heart, thyroid gland, kidneys, or adrenal glands, and the use of certain medications. Disorders of the lungs and certain cancers may increase the risk of developing SIADH. Treatment includes fluid restriction and sometimes the use of medications that decrease the effect of antidiuretic hormone on the kidneys.

Wikipedia : 74 Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is characterized by excessive... more...

Related Diseases for Inappropriate Adh Syndrome

Diseases related to Inappropriate Adh Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 601)
# Related Disease Score Top Affiliating Genes
1 nephrogenic syndrome of inappropriate antidiuresis 33.1 AVPR2 AVP
2 pure autonomic failure 30.9 REN NPPA
3 lung oat cell carcinoma 30.8 POMC AVP
4 pituitary apoplexy 30.6 POMC AVP
5 paralytic ileus 30.6 AVP ALB
6 sleep apnea 30.5 REN NPPB ALB
7 pituitary gland disease 30.5 POMC CRH AVP
8 malignant hypertension 30.5 REN NPPB NPPA
9 impotence 30.5 POMC OXT ALB
10 bartter disease 30.4 REN AVP AQP2
11 acute kidney failure 30.1 REN NPPA ALB
12 eclampsia 30.1 REN OXT ALB
13 congestive heart failure 30.1 REN NPPB NPPA AQP2 ALB
14 mental depression 30.0 POMC OXT CRH
15 pericardial effusion 30.0 REN NPPB NPPA ALB
16 respiratory failure 29.9 REN NPPB NPPA ALB
17 familial glucocorticoid deficiency 29.8 REN POMC CRH
18 peripheral nervous system disease 29.8 REN POMC AQP4 ALB
19 acquired immunodeficiency syndrome 29.8 POMC CRH ALB
20 liver cirrhosis 29.8 REN NPPA AVP AQP2 ALB
21 hydronephrosis 29.7 REN AQP2 ALB
22 brain edema 29.7 AQP4 AQP1 ALB
23 hypokalemia 29.6 REN POMC CRH AVPR2 AQP2 ALB
24 central pontine myelinolysis 29.6 AVPR2 AVP AQP4 AQP2 AQP1
25 pulmonary hypertension 29.3 REN NPPB NPPA ALB
26 stroke, ischemic 29.3 REN NPPB NPPA AVP AQP4 ALB
27 heart disease 29.3 REN NPPB NPPA AVPR2 AVP ALB
28 diabetes mellitus, type i 29.3 REN POMC NPPA ALB
29 intracranial hypertension 29.3 NPPB AVP AQP4 AQP1 ALB
30 pre-eclampsia 29.2 REN OXT NPPA CRH ALB
31 chronic kidney disease 29.1 REN POMC NPPB NPPA AVP AQP2
32 cardiac arrest 29.1 REN OXT NPPB AVP ALB
33 meniere disease 29.0 AQP4 AQP3 AQP2 AQP1
34 diabetes insipidus 29.0 REN POMC OXT CRH AVPR2 AVP
35 hepatorenal syndrome 28.9 REN NPPA AVP AQP2 AQP1 ALB
36 polycystic kidney disease 28.8 REN AVPR2 AVP AQP2 AQP1 ALB
37 schizophrenia 28.6 POMC OXT CRH AVP AQP4 ALB
38 hypertension, essential 28.2 REN POMC OXT NPPB NPPA CRH
39 autosomal dominant polycystic kidney disease 28.1 REN AVPR2 AVP AQP3 AQP2 AQP1
40 diabetes insipidus, nephrogenic, autosomal 27.9 REN OXT AVPR2 AVP AQP4 AQP3
41 small cell carcinoma 10.6
42 neuroendocrine carcinoma 10.5
43 hereditary nephrogenic diabetes insipidus 10.5 AVPR2 AQP2
44 ocular motor apraxia 10.5
45 olfactory neuroblastoma 10.5
46 neuroblastoma 10.5
47 herpes zoster 10.5
48 systemic lupus erythematosus 10.5
49 lupus erythematosus 10.5
50 small cell cancer of the lung 10.5

Graphical network of the top 20 diseases related to Inappropriate Adh Syndrome:



Diseases related to Inappropriate Adh Syndrome

Symptoms & Phenotypes for Inappropriate Adh Syndrome

UMLS symptoms related to Inappropriate Adh Syndrome:


polyuria

MGI Mouse Phenotypes related to Inappropriate Adh Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.14 AQP1 AQP2 AQP3 AQP4 AVP AVPR2
2 growth/size/body region MP:0005378 10.11 AQP1 AQP2 AQP3 AQP4 AVPR2 CPOX
3 homeostasis/metabolism MP:0005376 10.07 ALB AQP1 AQP2 AQP3 AQP4 AVP
4 hematopoietic system MP:0005397 10.02 AQP1 AQP2 AQP4 AVP AVPR2 CPOX
5 mortality/aging MP:0010768 9.93 ALB AQP1 AQP2 AQP3 AQP4 AVP
6 nervous system MP:0003631 9.61 AQP1 AQP4 AVP CPOX CRH LGI1
7 renal/urinary system MP:0005367 9.4 ALB AQP1 AQP2 AQP3 AQP4 AVP

Drugs & Therapeutics for Inappropriate Adh Syndrome

Drugs for Inappropriate Adh Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4 150683-30-0 216237
2 Vasopressins Phase 4
3 Arginine Vasopressin Phase 4
4 Hormones Phase 4
5 Liver Extracts Phase 4
6
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
7
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
8
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
9
Pegaspargase Approved, Investigational Phase 3 130167-69-0
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
12
leucovorin Approved Phase 3 58-05-9 6006 143
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
15
Mercaptopurine Approved Phase 3 50-44-2 667490
16
Lenograstim Approved, Investigational Phase 3 135968-09-1
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
19
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
20
Empagliflozin Approved Phase 2, Phase 3 864070-44-0
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
23
Satavaptan Investigational Phase 3 185913-78-4 7029
24 Deamino Arginine Vasopressin Phase 2, Phase 3
25 Etoposide phosphate Phase 3
26 Gastrointestinal Agents Phase 3
27 Micronutrients Phase 3
28 Vitamins Phase 3
29 Antidotes Phase 3
30 Folic Acid Antagonists Phase 3
31 Vitamin B Complex Phase 3
32
Liposomal doxorubicin Phase 3 31703
33 Antineoplastic Agents, Hormonal Phase 3
34 Antiemetics Phase 3
35 Anti-Infective Agents Phase 3
36 Hormone Antagonists Phase 3
37 Folate Phase 3
38 Dermatologic Agents Phase 3
39 Anti-Bacterial Agents Phase 3
40 Nutrients Phase 3
41 glucocorticoids Phase 3
42 Trace Elements Phase 3
43 Antiviral Agents Phase 3
44 N-Methylaspartate Phase 3
45 Tubulin Modulators Phase 3
46 Calcium, Dietary Phase 3
47 Protective Agents Phase 3
48 BB 1101 Phase 3
49 Vitamin B9 Phase 3
50 Antimetabolites Phase 3

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
2 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
3 Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia Terminated NCT02352285 Phase 4 Tolvaptan;Placebo
4 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
5 Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine Withdrawn NCT00298753 Phase 4
6 A Multicenter, Randomized, Double-blind, Placebo-controlled (Standard Therapy + Placebo) Study to Evaluate the Efficacy and Safety of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Unknown status NCT01507727 Phase 2, Phase 3 Tolvaptan;Placebo
7 A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
8 An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
9 A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Completed NCT03048747 Phase 3 Tolvaptan Oral Tablet
10 Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Completed NCT02729766 Phase 2, Phase 3 Empagliflozin 25mg Tbl;Placebo P-Tablet
11 Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
12 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia Completed NCT00274326 Phase 3 SR121463B
13 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia Completed NCT00660959 Phase 3 lixivaptan;placebo
14 Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Completed NCT02874807 Phase 2, Phase 3 Empagliflozin
15 Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2 Completed NCT00201994 Phase 3 Tolvaptan
16 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia Completed NCT00072683 Phase 3 tolvaptan
17 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia Completed NCT00876798 Phase 3 Lixivaptan;Placebo
18 Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Recruiting NCT03202667 Phase 2, Phase 3 Empagliflozin 25mg;Placebo
19 A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Terminated NCT00728091 Phase 3 Satavaptan;placebo
20 Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia Terminated NCT01227512 Phase 3 tolvaptan
21 A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA ® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia Terminated NCT02012959 Phase 3 Tolvaptan
22 A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan) Terminated NCT02020278 Phase 3 Tolvaptan
23 A Pilot Phase 3b,Multicenter,Randomized,Double-blind,Placebo-controlled Trial of the Safety,Efficacy,and Pharmacokinetics of Titrated Oral SAMSCA®(Tolvaptan) in Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Withdrawn NCT02442674 Phase 3 Tolvaptan
24 Hematological, Biochemical and Hemodynamic Changes During Operative Hysteroscopy Using Consecutive Distension Media Unknown status NCT03166228 Phase 2 Normal Saline 0.9% Infusion Solution Bag;1.5% Glycine only
25 A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT02009878 Phase 1, Phase 2 tolvaptan
26 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. Completed NCT00032734 Phase 2 satavaptan (SR121463B)
27 Randomized, Double-blind, Multicenter, Placebo-controlled (Standard Therapy + Placebo), Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Completed NCT00664014 Phase 2 Tolvaptan;Placebo
28 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
29 A Pilot Study To Evaluate The Incidence Of Hyponatremia In A Medical-Surgical Hospital And To Explore The Efficacy And Safety Of Tolvaptan In The Clinical Practice Terminated NCT01386372 Phase 2 Tolvaptan
30 Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies Terminated NCT00539656 Phase 1, Phase 2
31 Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial Terminated NCT00282438 Phase 1, Phase 2
32 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
33 A Multi-Centre, Multi-National, Observational Post-Authorisation Safety Study to Document the Drug Utilisation of Samsca and to Collect Information on the Safety of Samsca When Used in Routine Medical Practice Unknown status NCT01228682 Tolvaptan
34 Comparison of Ringer Lactate and Isotonic Acetate Solution as Maintenance Fluids in Children Undergoing Elective Laparoscopic Surgery Unknown status NCT02936167
35 A Non Interventional, Retrospective Study on Real World Usage and Treatment Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to the SIADH. Completed NCT02545101
36 An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization Completed NCT01240668
37 An Observational, Retrospective Study to Describe the Extent of Adherence to the Spanish Society of Medical Oncology Algorithm for the Treatment of Hyponatraemia Secondary to SIADH in Oncology Patients in Spain (ALGA) Completed NCT02548845
38 Spectrum of Serum Sodium Disturbances in Patients With Non-sellar/Suprasellar Supratentorial Tumors Completed NCT03570203
39 Comparison of the Vasopressin-2 Antagonist Tolvaptan and Fluid Restriction in the Treatment of Hyponatremia Following Pituitary Surgery Completed NCT04119206
40 A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy Completed NCT02573077
41 Water Load Test Value for Hyponatremia Due to a Syndrome of Inappropriate Antidiuresis (SIAD) Completed NCT04256499
42 Subclassification of the Syndrome of Inappropriate Antidiuresis Via Copeptin - What is the Genesis of ADH-independent SIADH? Completed NCT01341665
43 International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430 Completed NCT01056848
44 Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis Completed NCT01465672
45 Phenotypic Characterization of Neuropsychologic and Physical Performance in Geriatric Patients Suffering From Hyponatremia. Completed NCT02242604
46 Disturbances of the Sodium and Fluid Balance in Patients With Severe Traumatic Brain Injury and Non-traumatic Subarachnoid Hemorrhage. A Systematic Observational Study Completed NCT01313975
47 Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment) Completed NCT00390962
48 Prophylaxis Versus Treatment Against TURP Syndrome : Role of Hypertonic Saline Active, not recruiting NCT03428451 NaCl 3% HS;NaCl 3% HS;NaCl 0.9% NS
49 Standardization of Fluids in Inpatient Settings Active, not recruiting NCT03924674
50 Laser Prostatectomy for Benign Prostatic Hyperplasia: A Registry and Database Active, not recruiting NCT00159406

Search NIH Clinical Center for Inappropriate Adh Syndrome

Genetic Tests for Inappropriate Adh Syndrome

Anatomical Context for Inappropriate Adh Syndrome

MalaCards organs/tissues related to Inappropriate Adh Syndrome:

40
Pituitary, Lung, Kidney, Prostate, Heart, Thyroid, Adrenal Gland

Publications for Inappropriate Adh Syndrome

Articles related to Inappropriate Adh Syndrome:

(show top 50) (show all 756)
# Title Authors PMID Year
1
Hyponatremia and brain injury: absence of alterations of serum brain natriuretic peptide and vasopressin. 54 61
20069215 2009
2
[Hyponatraemia in patients with neurosurgical disorders: SIADH or cerebral salt wasting syndrome?]. 61 54
19885796 2009
3
Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. 61 54
18753429 2008
4
Hypothalamic-pituitary-adrenal axis and interleukin-6 activity in children with head trauma and syndrome of inappropriate secretion of antidiuretic hormone. 61 54
12585340 2003
5
Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. 61 54
11297601 2001
6
[Severe peripheral neuropathy, cardiac hypofunction, and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient with Churg-Strauss syndrome]. 61 54
10614173 1999
7
Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). 54 61
9100572 1997
8
A case of syndrome of inappropriate secretion of antidiuretic hormone associated with diabetes mellitus. 54 61
1794339 1991
9
Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of inappropriate secretion of antidiuretic hormone: an incidental or pathophysiological association? 61
31823899 2020
10
Nonosmotic secretion of arginine vasopressin and salt loss in hyponatremia in Kawasaki disease. 61
31657491 2020
11
Evolution and evolving resolution of controversy over existence and prevalence of cerebral/renal salt wasting. 61
31904619 2020
12
Long-term Survival of a Patient with Small Cell Lung Cancer Secreting ADH and ACTH Simultaneously, Following the Prolonged Use of Amrubicin. 61
31511478 2020
13
Acute symptomatic hyponatremia in setting of SIADH as an isolated presentation of COVID-19. 61
32523871 2020
14
Neurofibromatosis type 1-associated malignant peripheral nerve sheath tumour carcinomatous pleurisy: an autopsy case. 61
31346470 2019
15
Severe Hyponatremia Due to Cisplatin-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. 61
31641557 2019
16
A Study of Hyponatremia in Acute Encephalitis Syndrome: A Prospective Study From a Tertiary Care Center in India. 61
28393593 2019
17
Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases. 61
30637666 2019
18
A rare iatrogenic association of syndrome of inappropriate secretion of antidiuretic hormone, neuroleptic malignant syndrome and rhabdomyolysis. 61
30949348 2019
19
Pituitary macroadenoma presenting as severe hyponatremia: a case report. 61
30795800 2019
20
SIADH versus adrenal insufficiency: a life-threatening misdiagnosis. 61
30728045 2019
21
A case of drug-induced hypersensitivity syndrome induced by salazosulfapyridine combined with SIADH caused by interstitial pneumonia. 61
31534076 2019
22
Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor therapy in the perioperative period. 61
30843458 2019
23
A case report of a thymic neuroblastoma associated with syndrome of inappropriate secretion of antidiuretic hormone: Ten-year follow-up results after surgical treatment. 61
31005046 2019
24
Hyponatremia-Inducing Drugs. 61
32097944 2019
25
Chronic idiopathic hyponatremia in an elderly patient due to inappropriate antidiuretic hormone secretion (SIADH) syndrome. 61
32256039 2019
26
Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin. 61
30225740 2018
27
Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan. 61
29478867 2018
28
Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High? 61
29801549 2018
29
A study of atrial and brain natriuretic peptides in tuberculous meningitis and acute encephalitis. 61
29562995 2018
30
Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone. 61
29629516 2018
31
Syndrome of Inappropriate Secretion of Antidiuretic Hormone and Hyponatremia. 61
29292284 2018
32
Severe Solute Depletion in Patients with Hyponatremia Due to Diuretics Despite Biochemical Pictures Similar Than Those Observed in the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. 61
29990986 2018
33
Determining Fractional Urate Excretion Rates in Hyponatremic Conditions and Improved Methods to Distinguish Cerebral/Renal Salt Wasting From the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. 61
30560127 2018
34
[SMALL CELL PROSTATE CANCER PRODUCING SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE; A CASE REPORT]. 61
31631089 2018
35
Presenting Symptoms of Pituitary Apoplexy. 61
28437813 2018
36
[Syndrome of inappropriate secretion of antidiuretic hormone in multiple myeloma patients treated with bortezomib, lenalidomide, and dexamethasone combination therapy]. 61
30531137 2018
37
SIADH in Systemic JIA Resolving After Treatment With an IL-6 Inhibitor. 61
29242269 2018
38
A Case of Neurosarcoidosis-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone Diagnosed with Neuroendoscopy. 61
30158982 2018
39
[A CASE OF SUMMER-TYPE HYPERSENSITIVITY PNEUMONITIS ACCOMPANIED BY THE SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE]. 61
29459527 2018
40
Managing hyponatremia in lung cancer: latest evidence and clinical implications. 61
29344107 2017
41
Localized herpes zoster infection: a rare cause of syndrome of inappropriate secretion of antidiuretic hormone. 61
29230301 2017
42
Cerebral Salt-Wasting Syndrome: Diagnosis by Urine Sodium Excretion. 61
29078838 2017
43
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan. 61
28946972 2017
44
Syndrome of Inappropriate Secretion of Antidiuretic Hormone Preceding Guillain-Barré Syndrome. 61
29207765 2017
45
Electrolytes: Sodium Disorders. 61
28806046 2017
46
Dysnatremia as a poor prognostic indicator in patients with acute subarachnoid hemorrhage. 61
26496416 2017
47
Successful Radiotherapy for Advanced Small Cell Carcinoma of the Prostate with Syndrome of Inappropriate Secretion of Antidiuretic Hormone. 61
28567332 2017
48
[Atypical Guillain-Barre syndrome clustering: is it necessary to reconsider the diagnostic criteria and microbiological protocol?] 61
28444683 2017
49
Severe hyponatremia in a patient with schizophrenia associated with prolonged consciousness disturbance. 61
28509122 2017
50
Cerebral Salt Wasting Is the Most Common Cause of Hyponatremia in Stroke. 61
28110888 2017

Variations for Inappropriate Adh Syndrome

Cosmic variations for Inappropriate Adh Syndrome:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM89368095 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 4

Expression for Inappropriate Adh Syndrome

Search GEO for disease gene expression data for Inappropriate Adh Syndrome.

Pathways for Inappropriate Adh Syndrome

Pathways related to Inappropriate Adh Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080
2 Vasopressin-regulated water reabsorption hsa04962

Pathways related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 AVPR2 AVP AQP4 AQP3 AQP2 AQP1
2
Show member pathways
12.17 OXT NPPB NPPA AVP
3
Show member pathways
11.85 AVPR2 AVP AQP4 AQP3 AQP2 AQP1
4 11.62 POMC CRH AVPR2 AVP
5 11.38 REN NPPA AQP1
6 10.78 NPPB NPPA
7 10.66 AVPR2 AVP AQP4 AQP3 AQP2
8 10.17 POMC CRH

GO Terms for Inappropriate Adh Syndrome

Cellular components related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.03 REN POMC OXT NPPB NPPA CRH
2 extracellular space GO:0005615 9.61 REN POMC OXT NPPB NPPA LGI1
3 secretory granule GO:0030141 9.5 POMC OXT AVP
4 basolateral plasma membrane GO:0016323 9.46 AQP4 AQP3 AQP2 AQP1
5 extracellular region GO:0005576 9.32 REN POMC OXT NPPB NPPA LGI1

Biological processes related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.77 POMC NPPB NPPA
2 female pregnancy GO:0007565 9.76 OXT NPPA CRH
3 positive regulation of blood pressure GO:0045777 9.63 OXT AVPR2
4 response to immobilization stress GO:0035902 9.62 REN CRH
5 positive regulation of synaptic transmission GO:0050806 9.62 OXT LGI1
6 regulation of blood pressure GO:0008217 9.62 REN POMC NPPB NPPA
7 positive regulation of renal sodium excretion GO:0035815 9.61 OXT NPPB
8 grooming behavior GO:0007625 9.61 OXT AVP
9 maternal behavior GO:0042711 9.59 OXT AVP
10 cGMP biosynthetic process GO:0006182 9.58 NPPB NPPA
11 cGMP-mediated signaling GO:0019934 9.58 NPPB NPPA AQP1
12 positive regulation of systemic arterial blood pressure GO:0003084 9.57 AVPR2 AVP
13 receptor guanylyl cyclase signaling pathway GO:0007168 9.56 NPPB NPPA
14 drinking behavior GO:0042756 9.55 REN OXT
15 cellular water homeostasis GO:0009992 9.54 AQP4 AQP1
16 negative regulation of systemic arterial blood pressure GO:0003085 9.54 NPPB NPPA CRH
17 hyperosmotic salinity response GO:0042538 9.52 OXT AVP
18 negative regulation of urine volume GO:0035811 9.51 OXT AVPR2
19 response to ether GO:0045472 9.49 OXT CRH
20 maternal aggressive behavior GO:0002125 9.48 OXT AVP
21 cellular response to mercury ion GO:0071288 9.46 AQP2 AQP1
22 renal water transport GO:0003097 9.43 AQP2 AQP1
23 multicellular organismal water homeostasis GO:0050891 9.43 AVP AQP4 AQP1
24 water transport GO:0006833 9.35 AVP AQP4 AQP3 AQP2 AQP1
25 glycerol transport GO:0015793 9.33 AQP3 AQP2 AQP1
26 renal water homeostasis GO:0003091 9.1 AVPR2 AVP AQP4 AQP3 AQP2 AQP1

Molecular functions related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.7 REN POMC NPPB NPPA LGI1 CRH
2 channel activity GO:0015267 9.62 AQP4 AQP3 AQP2 AQP1
3 neuropeptide hormone activity GO:0005184 9.56 OXT NPPA CRH AVP
4 hormone receptor binding GO:0051427 9.46 NPPB NPPA
5 water transmembrane transporter activity GO:0005372 9.43 AQP2 AQP1
6 glycerol transmembrane transporter activity GO:0015168 9.4 AQP2 AQP1
7 neurohypophyseal hormone activity GO:0005185 9.37 OXT AVP
8 water channel activity GO:0015250 9.26 AQP4 AQP3 AQP2 AQP1
9 hormone activity GO:0005179 9.1 POMC OXT NPPB NPPA CRH AVP

Sources for Inappropriate Adh Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....